{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Part+1&page=16",
    "query": {
      "condition": "Part 1",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 403,
    "total_pages": 41,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Part+1&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Part+1&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T17:39:00.408Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03701555",
      "title": "A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Digestive System Disease"
      ],
      "interventions": [
        {
          "name": "PvP001 placebo",
          "type": "OTHER"
        },
        {
          "name": "PvP001 100 mg",
          "type": "DRUG"
        },
        {
          "name": "PvP001 300 mg",
          "type": "DRUG"
        },
        {
          "name": "PvP001 900 mg",
          "type": "DRUG"
        },
        {
          "name": "Maximum Feasible Dose (MFD) of PvP002",
          "type": "DRUG"
        },
        {
          "name": "Maximum Tolerated Dose (MTD) of PvP001",
          "type": "DRUG"
        },
        {
          "name": "MTD of PvP001 following 7 days of PPI treatment",
          "type": "DRUG"
        },
        {
          "name": "PvP002 placebo",
          "type": "OTHER"
        },
        {
          "name": "PvP001 600 mg",
          "type": "DRUG"
        },
        {
          "name": "PvP003 placebo",
          "type": "DRUG"
        },
        {
          "name": "PvP003",
          "type": "DRUG"
        },
        {
          "name": "PvP003 150 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 139,
      "start_date": "2018-06-19",
      "completion_date": "2021-07-02",
      "has_results": true,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-10-23T17:39:00.408Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03701555"
    },
    {
      "nct_id": "NCT06877702",
      "title": "A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "BMS-986460",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "18 Years to 60 Years · Male only"
      },
      "enrollment_count": 85,
      "start_date": "2025-03-19",
      "completion_date": "2025-12-17",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-10-23T17:39:00.408Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06877702"
    },
    {
      "nct_id": "NCT02637037",
      "title": "A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioequivalence",
        "Fixed Dose Combination Tablets",
        "Healthy Male and Female Subjects"
      ],
      "interventions": [
        {
          "name": "dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 80,
      "start_date": "2015-12-21",
      "completion_date": "2016-04-07",
      "has_results": true,
      "last_update_posted_date": "2018-03-13",
      "last_synced_at": "2026-10-23T17:39:00.408Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02637037"
    },
    {
      "nct_id": "NCT04802746",
      "title": "A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Study Participants",
        "Participants With Mild Asthma"
      ],
      "interventions": [
        {
          "name": "Alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 78,
      "start_date": "2021-03-09",
      "completion_date": "2021-11-22",
      "has_results": false,
      "last_update_posted_date": "2023-11-28",
      "last_synced_at": "2026-10-23T17:39:00.408Z",
      "location_count": 2,
      "location_summary": "North Dartmouth, Massachusetts • Raleigh, North Carolina",
      "locations": [
        {
          "city": "North Dartmouth",
          "state": "Massachusetts"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04802746"
    },
    {
      "nct_id": "NCT00219557",
      "title": "AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "AG-013736",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2005-07-05",
      "completion_date": "2008-03-14",
      "has_results": true,
      "last_update_posted_date": "2019-05-14",
      "last_synced_at": "2026-10-23T17:39:00.408Z",
      "location_count": 17,
      "location_summary": "Antioch, California • Berkeley, California • Concord, California + 11 more",
      "locations": [
        {
          "city": "Antioch",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00219557"
    },
    {
      "nct_id": "NCT03852446",
      "title": "Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Indoximod HCL (F2) tablets",
          "type": "DRUG"
        },
        {
          "name": "Indoximod base formulation",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NewLink Genetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 56,
      "start_date": "2018-03-05",
      "completion_date": "2018-08-14",
      "has_results": false,
      "last_update_posted_date": "2020-05-28",
      "last_synced_at": "2026-10-23T17:39:00.408Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03852446"
    },
    {
      "nct_id": "NCT07372625",
      "title": "A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "TP53 Y220C Mutation",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "metformin hydrochloride 500 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "rosuvastatin 10 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "repaglinide 0.5 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "midazolam hydrochloride syrup",
          "type": "DRUG"
        },
        {
          "name": "rezatapopt",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PMV Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2026-02-04",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-23T17:39:00.408Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07372625"
    },
    {
      "nct_id": "NCT03355209",
      "title": "A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lennox Gastaut Syndrome"
      ],
      "interventions": [
        {
          "name": "ZX008 0.2 or 0.8 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "2 Years to 35 Years"
      },
      "enrollment_count": 296,
      "start_date": "2017-11-27",
      "completion_date": "2024-05-23",
      "has_results": true,
      "last_update_posted_date": "2025-07-03",
      "last_synced_at": "2026-10-23T17:39:00.408Z",
      "location_count": 30,
      "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03355209"
    },
    {
      "nct_id": "NCT05418582",
      "title": "Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "DZD9008 and intraconazole",
          "type": "DRUG"
        },
        {
          "name": "DZD9008 and carbamazepine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dizal Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-01-25",
      "completion_date": "2022-12-08",
      "has_results": false,
      "last_update_posted_date": "2023-06-23",
      "last_synced_at": "2026-10-23T17:39:00.408Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05418582"
    },
    {
      "nct_id": "NCT07527923",
      "title": "First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer",
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "REGN20423",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 144,
      "start_date": "2026-05-22",
      "completion_date": "2028-06-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-23T17:39:00.408Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • North Little Rock, Arkansas • West Hills, California + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "West Hills",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "North Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07527923"
    }
  ]
}